What it is
BPC-157 is a synthetic 15 amino acid peptide. The sequence is based on a fragment of a protein found in human gastric juice, which is why Croatian researchers who first described it in the 1990s called it a body protection compound. It is not a hormone the body produces on its own; it is a laboratory construct built around that fragment because the fragment is unusually stable in the stomach's acid environment, where most peptides break down.
Almost everything published about BPC-157 comes from one long-running research program based in Zagreb, led by Predrag Sikiric and colleagues, plus a growing number of rat studies from other, separate laboratories since the late 2010s. The compound has never been an approved medicine anywhere.
How it works
BPC-157 has not been tied to a single receptor the way a hormone or a classic drug is. The research groups working on it describe several overlapping effects in rodents: it promotes formation of new blood vessels through pathways connected to VEGFR2, it interacts with the nitric oxide system, and it appears to modulate the activity of other growth factors rather than replacing them outright. Reviewers have called it a modulator of tissue-repair pathways rather than a single-target drug, which also makes its mechanism harder to pin down in a lab test.
Because the original research interest was gut protection, most of the foundational animal work is in models of stomach ulcers, colitis and surgical bowel connections (anastomoses) in rats. The tendon, ligament, muscle and brain research that dominates its current reputation online came later, largely from the same Zagreb group and collaborators.
What the research found
Animal studies. The published literature is overwhelmingly rodent work, almost all in rats, with some in mice. It covers:
- Surgically cut Achilles tendons, where treated rats showed better structural healing and cell migration into the tendon than untreated controls.
- Gut surgery models, including intestinal and esophagogastric anastomoses, colitis and short bowel syndrome, where BPC-157 sped healing and reduced tissue damage.
- Ligament, muscle and bone injury models, and a body of work on blood vessel formation that researchers argue underlies the other effects.
- A 2026 rat study compared BPC-157 and TB-500 directly on Achilles tendon healing, using biomechanical and tissue analysis; that head-to-head design is unusual and reflects how often the two are used together.
Human studies. We could not find a controlled human trial of injected BPC-157. The one published human report we found is a 2021 case series describing intra-articular BPC-157 injections in patients with knee pain, printed in a complementary-medicine journal rather than an orthopaedic one. A case series has no control group and cannot show that BPC-157 caused any change; it only documents that the injections were given. A 2025 narrative review of BPC-157 for musculoskeletal use reached a similar conclusion: the evidence base is built on rodents, and the human safety and efficacy picture remains largely unknown.
Side effects reported in studies
Because there is no controlled human trial, there is no human adverse-event data to summarise. The rodent literature generally reports BPC-157 as well tolerated at the doses tested, without the gastrointestinal bleeding or ulceration seen with some comparator drugs in the same experiments. That tells us about tolerability in rats, not about what an injected research-market vial does in a person, at whatever dose and purity that vial actually contains.
BPC-157 vs TB-500
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Fragment of a gastric juice protein | Fragment of thymosin beta-4 |
| Length | 15 amino acids | 7 amino acids (the short research-market version) |
| Evidence | Extensive rat and mouse studies; one human case series | Mostly studies of the full 43 amino acid protein, not the short fragment; some human trials of the full protein |
| WADA status | Not listed by name | Thymosin beta-4 is on the WADA Prohibited List |
| FDA compounding list | Nominated 2023, withdrawn April 2026 | Nominated 2023, withdrawn April 2026 |
Status in the Philippines
No BPC-157 product is registered with FDA Philippines as a medicine, and it is not a controlled substance under RA 9165. It is sold locally through research-peptide suppliers and is one of the most commonly stocked vials in that market, often alongside TB-500. In the US, FDA nominated it in 2023 for the list of bulk substances that may present significant safety risks in compounding, citing a lack of human safety information; that nomination was withdrawn in April 2026, and the substance is due for review by FDA's compounding advisory committee. Neither step amounts to approval.
Local stock BPC-157 20mg at Primara Labs, delivered in Metro Manila and nationwide. Research use only.
Storage
Keep the lyophilised powder refrigerated and away from light. Once reconstituted with bacteriostatic water, store at 2 to 8°C. During a brownout, move vials to a cooler with ice packs rather than letting a warming fridge sit unmonitored. The BPC-157 calculator and the reconstitution calculator handle the arithmetic. See the beginner guide for handling basics.
